Citius Pharmaceuticals Inc. (CTXR) Live Share Price, Invest From India

Citius Pharmaceuticals Inc. Stock Performance

as on July 22, 2026 at 6:59 am IST

Day's Low
Day's High
$0.49
Day's Price Range
$0.58
$0.56
12.50%
Downside
3.57%
Upside
52 Week's Low
52 Week's High
$0.47
52-Week Price Range
$2.19
$0.56
16.30%
Downside
291.07%
Upside

Citius Pharmaceuticals Inc. share price movements today

Previous Close: $0.48
Open: $0.49
Volume: 2.1M
Day's Low - High: $0.49 - $0.58
52 Week Low - High: $0.47 - $2.19

Citius Pharmaceuticals Inc. Historical Returns

1 Month Return: -15.6 %
3 Month Return: -44.11 %
1 Year Return: -67.08 %
3 Year Return: -98.36 %
5 Year Return: -99.04 %

Citius Pharmaceuticals Inc. Stock Fundamentals & Key Indicators

Check Citius Pharmaceuticals Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$13.6M

EPS (TTM)

-1.87

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-53.9M

Revenue (TTM)

5.6M

Profit Margin

0.00%

Return On Equity TTM

-83.60%

Citius Pharmaceuticals Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Citius Pharmaceuticals Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Citius Pharmaceuticals Inc.	BUY	$13.6M	-99.04%	NA	0.00%	NA
Revolution Medicines Inc.	BUY	$39.6B	529.19%	NA	0.00%	NA
Vertex Pharmaceuticals Inc.	BUY	$123.3B	145.13%	28.82	35.51%	NA
Regeneron Pharmaceuticals Inc.	BUY	$70.9B	14.53%	16.53	29.65%	0.53%

Stock Returns calculator for Citius Pharmaceuticals Inc. Stock including INR - Dollar returns

The Citius Pharmaceuticals Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Citius Pharmaceuticals Inc. investment value today

Current value as on today

₹42,824

Returns

-₹57,176

(-57.18%)

Returns from Citius Pharmaceuticals Inc. Stock

-₹61,644 (-61.64%)

Dollar Impact

₹4,468 (+4.47%)

Analyst Recommendation on Citius Pharmaceuticals Inc. Stock

Based on 9 analysts

BUY

88.89%

Buy

11.11%

Hold

0.00%

Sell

Based on 9 analysts, 88.89% of analysts recommend a 'BUY' rating for Citius Pharmaceuticals Inc.. Average target price of $4

Citius Pharmaceuticals Inc. Share Price Target

Get share price movements and forecasts by analysts on Citius Pharmaceuticals Inc..

What analysts predicted

86%UPSIDE

Target Price

Current Price

$0.56

Analyzed by

9 Analysts

Target

$4.00

Citius Pharmaceuticals Inc. target price $4, a slight upside of 86% compared to current price of $0.56. According to 9 analysts rating.

Indian Investors' Interest in Citius Pharmaceuticals Inc. Stock

Search interest for Citius Pharmaceuticals Inc. Stock has decreased by -19% in the last 30 days, reflecting a downward trend in search activity.

Time period: June 22, 2026 to July 22, 2026

Change:-19% versus previous 30 day period

Citius Pharmaceuticals Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	-	-	-	0	0	-	-	-	3	1
Gross Profit	0	0	0	0	0	0	0	0	2	0
Operating Income	-9	-10	-10	-11	-10	-11	-8	-8	-9	-32
EBITDA	-9	-10	-10	-10	-9	-11	-8	-8	-8	-30
Interest Expense	-	-	-	-	-	-	0	0	0	0
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-9	-8	-10	-10	-10	-11	-8	-8	-9	-28
Income Tax Expense	0	0	0	0	0	0	0	0	0	0
Net Income	-9	-8	-10	-10	-9	-10	-8	-7	-8	-21
Net Profit Margin	0.00%	0.00%	0.00%	-6920.05%	-6264.67%	0.00%	0.00%	0.00%	-208.43%	-1273.39%

Citius Pharmaceuticals Inc. Annual Profit & Loss

All numbers in Millions USD

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	0	0	0	0	0	0	0	0	0	0
Operating Income	-7	-9	-13	-15	-17	-23	-33	-36	-41	-38
EBITDA	-7	-9	-13	-15	-17	-22	-32	-31	-38	-38
Interest Expense	0	0	0	0	0	0	0	-	-	0
Depreciation	-	0	0	0	0	0	0	0	0	0
Income Before Tax	-8	-10	-12	-15	-17	-23	-33	-31	-38	-38
Income Tax Expense	0	0	1	0	0	0	0	0	0	1
Net Income	-8	-10	-12	-15	-17	-23	-33	-32	-39	-37
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Citius Pharmaceuticals Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-8	-10	-11	-10	-11	-9	-8	-9	-28
Operating Cash Flow	-7	-8	-5	-4	-4	-5	-11	-13	-1
Investing Cash Flow	-	-	-5	-5	-	-	-5	-4	0
Financing Cash Flow	-	13	-3	2	3	11	15	20	-1
Change in Cash	-7	5	-14	-2	-1	6	-1	3	-3

Citius Pharmaceuticals Inc. Annual Cash Flow

All numbers in Millions USD

	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Net Income	-10	-12	-15	-17	-23	-33	-32	-39	-39
Operating Cash Flow	-7	-11	-12	-16	-24	-28	-29	-28	-26
Investing Cash Flow	0	0	0	0	-40	-	-	-5	-5
Financing Cash Flow	10	17	11	22	120	0	13	9	33
Change in Cash	2	5	-1	5	56	-28	-15	-23	1

Global Institutional Holdings in Citius Pharmaceuticals Inc.

Funds	Holdings
Susquehanna International Group, LLP	0.13%
CAMBRIDGE Invest RESEARCH ADVISORS, INC.	0.04%
XTX Topco Ltd	0.08%
Miller Financial Services LLC	0.05%
HRT FINANCIAL LLC	0.22%

See all

Insights on Citius Pharmaceuticals Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 3 years, Revolution Medicines, Inc. Common Stock has given 573.9% return, outperforming this stock by 672.3%
NO EFFECT
Against Peers
In the last 1 year, Revolution Medicines, Inc. Common Stock has given 369.5% return, outperforming this stock by 436.1%
NEGATIVE IMPACT
Price Dip
In the last 3 months, CTXR stock has moved down by -43.1%

About Citius Pharmaceuticals Inc.

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Organisation	Citius Pharmaceuticals Inc.
Headquarters	11 Commerce Drive, Cranford, NJ, United States, 07016
Industry	Biotechnology
CEO	Mr. Leonard L. Mazur
E-voting on shares	Click here to vote

Key Management of Citius Pharmaceuticals Inc.

Name	Title
Mr. Gary F. Talarico	Executive Vice President of Operations
Mr. Kelly Creighton Ph.D.	Executive Vice President of Chemistry, Manufacturing & Controls
Mr. Nikolas Burlew	Executive Vice President of Quality Assurance
Mr. Leonard L. Mazur	Co-Founder, CEO, Chairman & Secretary
Mr. Myron Z. Holubiak	Co-Founder & Executive Vice Chairman
Ms. Ilanit Allen	Vice President of Investor Relations & Corporate Communications
Dr. Alan Lader Ph.D.	Senior VP and Head of Clinical Operations & Quality Assurance
Mr. Dhananjay G. Wadekar	Senior Vice President of Business Strategy
Dr. Myron S. Czuczman M.D.	Executive VP & Chief Medical Officer
Mr. Jaime Bartushak	Chief Business Officer & CFO

FAQs

What is Citius Pharmaceuticals Inc. share price today?

Citius Pharmaceuticals Inc. share price today is $0.56 as on July 22, 2026 at 1:29 am IST at the close of the market. Citius Pharmaceuticals Inc. share today touched a day high of $0.58 and a low of $0.49.

What is the 52 week high and 52 week low for Citius Pharmaceuticals Inc. share?

Citius Pharmaceuticals Inc. share touched a 52 week high of $2.19 on October 20, 2025 and a 52 week low of $0.47 on July 20, 2026. Citius Pharmaceuticals Inc. stock price today i.e. July 22, 2026 at 1:29 am IST is closed at $0.56,which is 74.43% down from its 52 week high and 19.48% up from its 52 week low.

What is Citius Pharmaceuticals Inc.'s market capitalisation today?

Citius Pharmaceuticals Inc. market capitalisation is $0.00T as on July 22, 2026 at 1:29 am IST.

How to invest in Citius Pharmaceuticals Inc. Stock (CTXR) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Citius Pharmaceuticals Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Citius Pharmaceuticals Inc. Shares that will get you 2.6786 shares as per Citius Pharmaceuticals Inc. share price of $0.56 per share as on July 22, 2026 at 1:29 am IST.

What is the minimum amount required to buy Citius Pharmaceuticals Inc. Stock (CTXR) from India?

Indian investors can start investing in Citius Pharmaceuticals Inc. (CTXR) shares with as little as ₹96.235 or $1 (as of July 22, 2026 at 2:47 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹962.35 in Citius Pharmaceuticals Inc. stock (as per the Rupee-Dollar exchange rate as on July 22, 2026 at 2:47 am IST). Based on Citius Pharmaceuticals Inc. share’s latest price of $0.56 as on July 22, 2026 at 1:29 am IST, you will get 17.8571 shares of Citius Pharmaceuticals Inc.. Learn more about fractional shares .

What are the returns that Citius Pharmaceuticals Inc. has given to Indian investors in the last 5 years?

Citius Pharmaceuticals Inc. stock has given -99.04% share price returns and 29.47% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?